AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
AVITA Medical, Inc.NASDAQ: RCEL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $627K rose 20.3% year over year, behind the +69.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.4% from the prior quarter. Over 3 fiscal years it compounded at +60.5% a year.
Context
- Depreciation & amortization amounted to 3.3% of revenue in FY2025, up 1.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.3% toward the trailing-twelve-month pace of +69.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.35M USD
- Year-over-year change
- +108.4%
- 4-year CAGR
- +36.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.35M | +108.4% |
| FY2024 | 2024-12-31 | 1.13M | +78.2% |
| FY2023 | 2023-12-31 | 632K | +11.3% |
| FY2022 | 2022-12-31 | 568K | -15.6% |
| FY2021 | 2021-12-31 | 673K | — |
Depreciation & Amortization vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 depreciation & amortization of $2.45M is the 4th highest of the 9 companies compared; the peer median is $1.21M.
- Its year-over-year change of +69.9% is the highest of 9, against a peer median of +3.8%.
- Depreciation & amortization amounts to 3.4% of revenue for RCEL, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.68M | +9.1% | +59.1% | 3.8% | |
| LTM Mar 2026 | $4.52M | -1.6% | +1.2% | 4.3% | |
| LTM Mar 2026 | $3.64M | -3.9% | +6.3% | 364.3% | |
| LTM Mar 2026 | $2.45M | +69.9% | +60.5% | 3.4% | |
| LTM Mar 2026 | $1.55M | +59.1% | +29.4% | 10.1% | |
| LTM Mar 2026 | $873K | -1.6% | -23.3% | 17.0% | |
| LTM Mar 2026 | $687K | +18.4% | -9.7% | 1.2% | |
| LTM Mar 2026 | $452K | +12.2% | +3.6% | — | |
| LTM Mar 2026 | $167K | -73.0% | -39.9% | 2.3% | |
| Peer median (excluding RCEL) | $1.21M | +3.8% | +2.4% | 4.3% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.03M | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 26.92M | 28.38M | 42.36M | 55.16M | 58.82M |
| Gross Margin | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| Research & Development | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M |
| Selling, General & Admin | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M |
| Operating Expenses | 52.04M | 55.89M | 85.02M | 111.75M | 100.75M |
| Depreciation & Amortization | 673K | 568K | 632K | 1.13M | 2.35M |
| EBITDA | (24.4M) | (26.05M) | (33.54M) | (55.3M) | (39.59M) |
| EBITDA Margin | -73.9% | -75.7% | -66.9% | -86.1% | -55.3% |
| Operating Income | (25.12M) | (27.51M) | (42.66M) | (56.59M) | (41.93M) |
| Operating Margin | -76.1% | -79.9% | -85.1% | -88.1% | -58.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 29K | 16K | 1.14M | 5.36M | 5M |
| Other Income / Expenses | 18K | 876K | 7.34M | (5.2M) | (6.64M) |
| Income Before Tax | (25.1M) | (26.63M) | (35.32M) | (61.79M) | (48.58M) |
| Pre-Tax Margin | -76.0% | -77.4% | -70.4% | -96.2% | -67.8% |
| Income Tax Expense | 42K | 36K | 66K | 54K | 11K |
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Net Margin | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (Basic) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| EPS (Diluted) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| Weighted Avg Shares | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
| Weighted Avg Shares (Diluted) | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.